Last updated on September 2018

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations


Brief description of study

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Clinical Study Identifier: NCT02864992

Contact Investigators or Research Sites near you

Start Over

Maria Sereno Moyano

Hospital Universitario Infanta Sofia
San Sebastian de los Reyes, Spain
  Connect »

Javier de Castro Carpeño

Hospital Universitario HM Madrid Sanchinarro
Madrid, Spain
6.19miles
  Connect »

Pilar Lopez Criado

MD Anderson Cancer Centre
Madrid, Spain
7.42miles
  Connect »

Javier de Castro Carpeño

Hospital Universitario La Paz
Madrid, Spain
8.28miles
  Connect »